Fidelity Investments’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
Fidelity Investments's ARCT Position: Q3 2026 in Review
Fidelity Investments reduced its Arcturus Therapeutics (ARCT) stake by 63% in Q3 2026, selling an estimated $129K and leaving 7,234 shares worth $99K. The position accounts for ﹤0.01% of the portfolio, ranked #4026.
Fidelity Investments first reported a position in ARCT in Q3 2019 and has held it in 29 quarters since. The position peaked at $51.3M in Q3 2021. 155 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.
- Fidelity Investments held 7,234 shares of Arcturus Therapeutics worth $99K as of Q3 2026.
- Fidelity Investments sold 12,308 Arcturus Therapeutics shares in Q3 2026, an estimated $129K.
- Arcturus Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #4026 holding.
- Fidelity Investments first reported a position in Arcturus Therapeutics in Q3 2019 and has held it in 29 quarters since.
- Fidelity Investments's Arcturus Therapeutics position peaked at $51.3M in Q3 2021.
- 155 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.
Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.